Market Cap 462.57M
Revenue (ttm) 35.95M
Net Income (ttm) -104.99M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -292.04%
Debt to Equity Ratio 0.00
Volume 2,363,300
Avg Vol 3,152,394
Day's Range N/A - N/A
Shares Out 123.03M
Stochastic %K 16%
Beta 2.94
Analysts Strong Sell
Price Target $13.33

Company Profile

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epi...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 231 0700
Address:
490 Arsenal Way, Suite120, Watertown, United States
Andysss
Andysss Sep. 4 at 12:36 PM
$CCCC rate hike incoming
0 · Reply
zawojak
zawojak Sep. 3 at 7:24 PM
$CCCC in general it was the sheiiittest trading year for me since 2022. Idk what's need to happen so the market comes back to "normal".
0 · Reply
venice868
venice868 Sep. 3 at 12:27 PM
$CCCC today announced that new biomarker data on the immunomodulatory effects of cemsidomide in combination with dexamethasone from its Phase 1 trial for relapsed/refractory multiple myeloma (RRMM) will be presented in a poster at the 23rd IMS Annual Meeting. The data characterize the immune effects on T cells and natural killer (NK) cells across the once-daily dose levels evaluated in the Phase 1 trial, further supporting cemsidomide's potential as a combination partner for immune-based therapies. The meeting will take place in Glasgow, Scotland from September 23 – 26, 2026.
0 · Reply
venice868
venice868 Sep. 2 at 4:31 PM
$CCCC thanks for the dips
0 · Reply
zawojak
zawojak Sep. 2 at 2:09 PM
$CCCC squeeze time? Long overdue!
0 · Reply
buho
buho Sep. 2 at 1:13 AM
$CCCC What do the shorts see? Mar 13: 13.5M Mar 31: 16.2M Apr 30: 21.1M May 29: 21.7M Jun 30: 25.0M Jul 15: 23.8M Jul 31: 30.4M Aug 14: 34.05M That they continue in the abyss.
0 · Reply
vu_jade
vu_jade Sep. 1 at 7:26 PM
$CCCC Constructive
0 · Reply
JuggernautRaider
JuggernautRaider Sep. 1 at 11:22 AM
$TNXP $IMRX $CCCC $ALT Hey America can you come get this guy? He is clearly on something. Why are Christians so dramatic as Marcus Aurelius called us in “Meditations”? Hmm 🧐 https://www.linkedin.com/pulse/why-ohio-friday-night-lights-have-never-been-beaten-ask-jeff-conroy-tkmse
1 · Reply
investfreakycat
investfreakycat Sep. 1 at 3:00 AM
$CCCC IMS Annual Meeting, September 23 - 26, 2026: Present a poster featuring additional biomarker data on cemsidomide’s immunomodulatory effects on T cells and NK cells in combination with dexamethasone.
1 · Reply
JuggernautRaider
JuggernautRaider Aug. 29 at 12:46 PM
What’s my position in what? I need specifics sir 🧐 $SLS ? $TNXP ? $ALT ? $CCCC ??? En garde, mon ami! ⚔️
1 · Reply
Latest News on CCCC
C4 Therapeutics reports Q2 EPS (18c), consensus (23c)

2026-08-11T11:10:28.000Z - 27 days ago

C4 Therapeutics reports Q2 EPS (18c), consensus (23c)


C4 Therapeutics Earnings release: Q2 2026

Aug 11, 2026, 7:00 AM EDT - 27 days ago

C4 Therapeutics Earnings release: Q2 2026


C4 Therapeutics Quarterly report: Q2 2026

Aug 11, 2026, 7:00 AM EDT - 27 days ago

C4 Therapeutics Quarterly report: Q2 2026


C4 Therapeutics Slides: Corporate presentation

Aug 10, 2026, 7:00 AM EDT - 4 weeks ago

C4 Therapeutics Slides: Corporate presentation


C4 Therapeutics Transcript: AGM 2026

Jun 24, 2026, 8:30 AM EDT - 2 months ago

C4 Therapeutics Transcript: AGM 2026


C4 Therapeutics Transcript: KOL event

Jun 18, 2026, 9:00 AM EDT - 2 months ago

C4 Therapeutics Transcript: KOL event


C4 Therapeutics Slides: KOL event

Jun 18, 2026, 9:00 AM EDT - 2 months ago

C4 Therapeutics Slides: KOL event


C4 Therapeutics Slides: Corporate presentation

Jun 11, 2026, 7:00 AM EDT - 2 months ago

C4 Therapeutics Slides: Corporate presentation


C4 Therapeutics jumps after Bristol Myers myeloma data

2026-05-29T15:51:38.000Z - 3 months ago

C4 Therapeutics jumps after Bristol Myers myeloma data

BMY


C4 Therapeutics to Participate in Upcoming Conferences

May 20, 2026, 7:00 AM EDT - 3 months ago

C4 Therapeutics to Participate in Upcoming Conferences


C4 Therapeutics reports Q1 EPS (20c), consensus (26c)

2026-05-12T12:40:38.000Z - 3 months ago

C4 Therapeutics reports Q1 EPS (20c), consensus (26c)


C4 Therapeutics Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 3 months ago

C4 Therapeutics Quarterly report: Q1 2026


C4 Therapeutics Earnings release: Q1 2026

May 12, 2026, 7:00 AM EDT - 3 months ago

C4 Therapeutics Earnings release: Q1 2026


C4 Therapeutics Slides: Investor presentation

May 12, 2026, 7:00 AM EDT - 3 months ago

C4 Therapeutics Slides: Investor presentation


C4 Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

C4 Therapeutics Proxy statement: Proxy filing


C4 Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

C4 Therapeutics Proxy statement: Proxy filing


C4 Therapeutics expands long-term partnership with Roche

2026-04-09T11:07:07.000Z - 5 months ago

C4 Therapeutics expands long-term partnership with Roche


C4 Therapeutics Slides: Corporate presentation

Apr 8, 2026, 7:00 AM EDT - 5 months ago

C4 Therapeutics Slides: Corporate presentation


C4 Therapeutics doses first patient in cemsidomide trial

2026-03-25T11:25:28.000Z - 5 months ago

C4 Therapeutics doses first patient in cemsidomide trial


C4 Therapeutics Slides: Corporate presentation

Mar 2, 2026, 6:00 AM EST - 6 months ago

C4 Therapeutics Slides: Corporate presentation


C4 Therapeutics price target raised to $7 from $5 at Barclays

2026-02-27T10:25:32.000Z - 6 months ago

C4 Therapeutics price target raised to $7 from $5 at Barclays


C4 Therapeutics reports Q4 EPS (18c), consensus (34c)

2026-02-26T12:08:51.000Z - 6 months ago

C4 Therapeutics reports Q4 EPS (18c), consensus (34c)


C4 Therapeutics Annual report: Q4 2025

Feb 26, 2026, 7:00 AM EST - 6 months ago

C4 Therapeutics Annual report: Q4 2025


C4 Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 7:00 AM EST - 6 months ago

C4 Therapeutics Earnings release: Q4 2025


C4 Therapeutics Slides: Corporate presentation

Feb 25, 2026, 7:00 AM EST - 6 months ago

C4 Therapeutics Slides: Corporate presentation


C4 Therapeutics to Participate in Upcoming March Conferences

Feb 23, 2026, 7:10 AM EST - 6 months ago

C4 Therapeutics to Participate in Upcoming March Conferences


C4 Therapeutics outlines milestones through 2028

2026-01-14T12:05:59.000Z - 7 months ago

C4 Therapeutics outlines milestones through 2028


C4 Therapeutics price target lowered to $5 from $10 at Barclays

2025-12-17T10:55:09.000Z - 8 months ago

C4 Therapeutics price target lowered to $5 from $10 at Barclays


C4 Therapeutics initiated with a Buy at TD Cowen

2025-12-02T10:40:12.000Z - 9 months ago

C4 Therapeutics initiated with a Buy at TD Cowen


C4 Therapeutics files $400M mixed securities shelf

2025-11-21T21:10:22.000Z - 9 months ago

C4 Therapeutics files $400M mixed securities shelf


C4 Therapeutics Registration statement: Registration Filing

Nov 21, 2025, 7:00 AM EST - 9 months ago

C4 Therapeutics Registration statement: Registration Filing


C4 Therapeutics reports Q3 EPS (44c), consensus (38c)

2025-11-06T12:24:51.000Z - 10 months ago

C4 Therapeutics reports Q3 EPS (44c), consensus (38c)


C4 Therapeutics sees cash runway to the end of 2028

2025-11-06T12:24:45.000Z - 10 months ago

C4 Therapeutics sees cash runway to the end of 2028


C4 Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 10 months ago

C4 Therapeutics Earnings release: Q3 2025


C4 Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 10 months ago

C4 Therapeutics Quarterly report: Q3 2025


C4 Therapeutics Slides: Corporate Presentation

Nov 5, 2025, 6:00 PM EST - 10 months ago

C4 Therapeutics Slides: Corporate Presentation


C4 Therapeutics Slides: Corporate Presentation

Nov 4, 2025, 6:00 PM EST - 10 months ago

C4 Therapeutics Slides: Corporate Presentation


C4 Therapeutics prices $125M underwritten offering

2025-10-16T11:20:33.000Z - 10 months ago

C4 Therapeutics prices $125M underwritten offering


C4 Therapeutics price target raised to $10 from $8 at Barclays

2025-09-22T11:15:14.000Z - 11 months ago

C4 Therapeutics price target raised to $10 from $8 at Barclays


C4 Therapeutics Transcript: Status Update

Sep 20, 2025, 3:00 PM EDT - 11 months ago

C4 Therapeutics Transcript: Status Update


C4 Therapeutics Slides: Status Update

Sep 20, 2025, 3:00 PM EDT - 11 months ago

C4 Therapeutics Slides: Status Update


C4 Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 1 year ago

C4 Therapeutics Earnings release: Q2 2025


C4 Therapeutics Quarterly report: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 1 year ago

C4 Therapeutics Quarterly report: Q2 2025


C4 Therapeutics Earnings release: Q1 2025

May 7, 2025, 7:00 AM EDT - 1 year ago

C4 Therapeutics Earnings release: Q1 2025


C4 Therapeutics Quarterly report: Q1 2025

May 7, 2025, 7:00 AM EDT - 1 year ago

C4 Therapeutics Quarterly report: Q1 2025


C4 Therapeutics Slides: Corporate Presentation

May 7, 2025, 7:00 AM EDT - 1 year ago

C4 Therapeutics Slides: Corporate Presentation


C4 Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

C4 Therapeutics Proxy statement: Proxy Filing


C4 Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

C4 Therapeutics Proxy statement: Proxy Filing


C4 Therapeutics Proxy statement: Proxy Filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

C4 Therapeutics Proxy statement: Proxy Filing


C4 Therapeutics Earnings release: Q4 2024

Feb 27, 2025, 7:00 AM EST - 1 year ago

C4 Therapeutics Earnings release: Q4 2024


C4 Therapeutics Annual report: Q4 2024

Feb 27, 2025, 7:00 AM EST - 1 year ago

C4 Therapeutics Annual report: Q4 2024


C4 Therapeutics Slides: Corporate Presentation

Feb 26, 2025, 7:00 AM EST - 1 year ago

C4 Therapeutics Slides: Corporate Presentation


C4 Therapeutics Slides: FY 2025

Jan 15, 2025, 5:15 PM EST - 1 year ago

C4 Therapeutics Slides: FY 2025


C4 Therapeutics Transcript: Status Update

Dec 8, 2024, 5:00 PM EST - 1 year ago

C4 Therapeutics Transcript: Status Update


C4 Therapeutics Slides: Status Update

Dec 8, 2024, 5:00 PM EST - 1 year ago

C4 Therapeutics Slides: Status Update


C4 Therapeutics Registration statement: Registration Filing

Oct 31, 2024, 8:00 AM EDT - 1 year ago

C4 Therapeutics Registration statement: Registration Filing


C4 Therapeutics Registration statement: Registration Filing

Oct 31, 2024, 8:00 AM EDT - 1 year ago

C4 Therapeutics Registration statement: Registration Filing


C4 Therapeutics Quarterly report: Q3 2024

Oct 31, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Quarterly report: Q3 2024


C4 Therapeutics Earnings release: Q3 2024

Oct 31, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Earnings release: Q3 2024


C4 Therapeutics Transcript: Study Update

Sep 13, 2024, 12:00 PM EDT - 1 year ago

C4 Therapeutics Transcript: Study Update


C4 Therapeutics Press release: Study Update

Sep 13, 2024, 12:00 PM EDT - 1 year ago

C4 Therapeutics Press release: Study Update


C4 Therapeutics Slides: Study Update

Sep 13, 2024, 12:00 PM EDT - 1 year ago

C4 Therapeutics Slides: Study Update


C4 Therapeutics Quarterly report: Q2 2024

Aug 1, 2024, 7:04 AM EDT - 2 years ago

C4 Therapeutics Quarterly report: Q2 2024


C4 Therapeutics Earnings release: Q2 2024

Aug 1, 2024, 7:04 AM EDT - 2 years ago

C4 Therapeutics Earnings release: Q2 2024


C4 Therapeutics Quarterly report: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics Quarterly report: Q1 2024


C4 Therapeutics Earnings release: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics Earnings release: Q1 2024


C4 Therapeutics Slides: Corporate Presentation

May 7, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics Slides: Corporate Presentation


C4 Therapeutics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

C4 Therapeutics Proxy statement: Proxy Filing


C4 Therapeutics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

C4 Therapeutics Proxy statement: Proxy Filing


C4 Therapeutics Earnings release: Q4 2023

Feb 22, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics Earnings release: Q4 2023


C4 Therapeutics Annual report: Q4 2023

Feb 22, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics Annual report: Q4 2023


C4 Therapeutics Slides: FY 2024

Jan 11, 2024, 12:00 PM EST - 2 years ago

C4 Therapeutics Slides: FY 2024


C4 Therapeutics Slides: Corporate Presentation

Jan 11, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics Slides: Corporate Presentation


C4 Therapeutics Transcript: Study Update

Dec 12, 2023, 4:30 PM EST - 2 years ago

C4 Therapeutics Transcript: Study Update


C4 Therapeutics Quarterly report: Q3 2023

Nov 1, 2023, 8:00 AM EDT - 2 years ago

C4 Therapeutics Quarterly report: Q3 2023


C4 Therapeutics Earnings release: Q3 2023

Nov 1, 2023, 8:00 AM EDT - 2 years ago

C4 Therapeutics Earnings release: Q3 2023


Andysss
Andysss Sep. 4 at 12:36 PM
$CCCC rate hike incoming
0 · Reply
zawojak
zawojak Sep. 3 at 7:24 PM
$CCCC in general it was the sheiiittest trading year for me since 2022. Idk what's need to happen so the market comes back to "normal".
0 · Reply
venice868
venice868 Sep. 3 at 12:27 PM
$CCCC today announced that new biomarker data on the immunomodulatory effects of cemsidomide in combination with dexamethasone from its Phase 1 trial for relapsed/refractory multiple myeloma (RRMM) will be presented in a poster at the 23rd IMS Annual Meeting. The data characterize the immune effects on T cells and natural killer (NK) cells across the once-daily dose levels evaluated in the Phase 1 trial, further supporting cemsidomide's potential as a combination partner for immune-based therapies. The meeting will take place in Glasgow, Scotland from September 23 – 26, 2026.
0 · Reply
venice868
venice868 Sep. 2 at 4:31 PM
$CCCC thanks for the dips
0 · Reply
zawojak
zawojak Sep. 2 at 2:09 PM
$CCCC squeeze time? Long overdue!
0 · Reply
buho
buho Sep. 2 at 1:13 AM
$CCCC What do the shorts see? Mar 13: 13.5M Mar 31: 16.2M Apr 30: 21.1M May 29: 21.7M Jun 30: 25.0M Jul 15: 23.8M Jul 31: 30.4M Aug 14: 34.05M That they continue in the abyss.
0 · Reply
vu_jade
vu_jade Sep. 1 at 7:26 PM
$CCCC Constructive
0 · Reply
JuggernautRaider
JuggernautRaider Sep. 1 at 11:22 AM
$TNXP $IMRX $CCCC $ALT Hey America can you come get this guy? He is clearly on something. Why are Christians so dramatic as Marcus Aurelius called us in “Meditations”? Hmm 🧐 https://www.linkedin.com/pulse/why-ohio-friday-night-lights-have-never-been-beaten-ask-jeff-conroy-tkmse
1 · Reply
investfreakycat
investfreakycat Sep. 1 at 3:00 AM
$CCCC IMS Annual Meeting, September 23 - 26, 2026: Present a poster featuring additional biomarker data on cemsidomide’s immunomodulatory effects on T cells and NK cells in combination with dexamethasone.
1 · Reply
JuggernautRaider
JuggernautRaider Aug. 29 at 12:46 PM
What’s my position in what? I need specifics sir 🧐 $SLS ? $TNXP ? $ALT ? $CCCC ??? En garde, mon ami! ⚔️
1 · Reply
buho
buho Aug. 27 at 8:33 PM
$CCCC great effort being applied to keep this under $4.30
0 · Reply
JuggernautRaider
JuggernautRaider Aug. 26 at 8:46 PM
$TNXP who cares about money when we have human brothers and sisters whose souls are burning in Hell right now? We can unleash them. How about Psalm 41? Who needs some healing? Click this link for some beautiful healing scripture 📕 🙏 💚 https://www.biblegateway.com/passage/?search=Psalm%2041&version=NIV $ALT $CCCC $GMAB why not?
0 · Reply
QuantInsider
QuantInsider Aug. 26 at 8:43 PM
$CCCC seeing some interesting action Big call sweeps coming in strong We’re talking 3,672 contracts over 5 days All ask-side, zero put flow That’s $550K in premium with an average of 350 days to expiry Feels like someone’s betting on long-term upside Especially with that recent +4.2% price move The big one is a 1,272-contract sweep on Dec 2027 $4 calls at $2.20 Open interest was only 100 so this looks like a new LEAPS position Strong bullish vibe but it’s slow-burning Short-term traders might want to wait for more near-dated action or a price push before diving in
0 · Reply
vu_jade
vu_jade Aug. 25 at 2:03 PM
$CCCC ready again
0 · Reply
open_outcry
open_outcry Aug. 24 at 1:06 PM
$CCCC i can't understand the ppl (algos?) that choose to short this stock. a high-risk/low-reward proposition if i've ever seen one.
1 · Reply
investfreakycat
investfreakycat Aug. 21 at 4:31 AM
$CCCC 🧐 on its way to 6.5?
1 · Reply
JuggernautRaider
JuggernautRaider Aug. 20 at 8:20 PM
$IXHL hmm so much potential 😋 $CCCC $CGEM $GMAB also woah 😋 🍱 🍣
0 · Reply
vu_jade
vu_jade Aug. 20 at 7:33 PM
$CCCC to much cash .. to much potential
0 · Reply
buho
buho Aug. 19 at 11:58 PM
$CCCC though I like to see natural progression with CCCC, short interest is very high. Be satisfying to see a squeeze develop. 30 mil shares short. Waiting on threshold if shorts starting to step on their own feet.
0 · Reply
cor1
cor1 Aug. 19 at 10:49 PM
$CCCC Cup and handle forming?
0 · Reply
Andysss
Andysss Aug. 19 at 2:09 PM
$CCCC wake up. All my other bios is up sig. Treasury said it would at least double long-end liquidity-support buybacks starting Sept. 9.
1 · Reply
Jh900
Jh900 Aug. 18 at 2:50 PM
$CCCC nice entry ready for this to reach 5
0 · Reply